Serum Urate and Incidence of Kidney Disease Among Veterans with Gout

被引:32
|
作者
Krishnan, Eswar [1 ]
Akhras, Kasem S. [2 ]
Sharma, Hari [3 ]
Marynchenko, Maryna [3 ]
Wu, Eric [3 ]
Tawk, Rima H. [2 ]
Liu, Jinan [4 ,5 ]
Shi, Lizheng [4 ,5 ]
机构
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Takeda Pharmaceut Int Inc, Deerfield, IL USA
[3] Anal Grp Inc, Boston, MA 02199 USA
[4] Tulane Univ, New Orleans, LA 70118 USA
[5] Southeast Louisiana Vet Hlth Care Syst, New Orleans, LA USA
关键词
SERUM URATE; URIC ACID; GOUT; KIDNEY DISEASE; HYPERURICEMIA; ACUTE-RENAL-FAILURE; URIC-ACID; RISK-FACTOR; HYPERURICEMIA; PROGRESSION; HYPERTENSION; PREVALENCE; MARKER; ESRD; CKD;
D O I
10.3899/jrheum.121061
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To study the association between serum urate level (sUA) and the risk of incident kidney disease among US veterans with gouty arthritis. Methods. From 2002 through 2011 adult male patients with gout who were free of kidney disease were identified in the data from the Veterans Administration VISN 16 database and were followed until incidence of kidney disease, death, or the last available observation. Accumulated hazard curves for time to kidney disease were estimated for patients with average sUA levels > 7 mg/dl (high) versus <= 7 mg/dl (low) based on Kaplan-Meier analyses; and statistical comparison was conducted using a log-rank test. A Cox proportional hazard model with time-varying covariates was used to estimate the unadjusted and adjusted hazard ratios for kidney disease. Results. Eligible patients (n = 2116) were mostly white (53%), with average age 62.6 years, mean body mass index 31.2 kg/m(2), and high baseline prevalence of hypertension (93%), hyperlipidemia (67%), and diabetes (20%). Mean followup time was 6.5 years. The estimated rates of all incident kidney disease in the overall low versus high sUA groups were 2% versus 4% at Year 1, 3% versus 6% at Year 2, and 5% versus 9% at Year 3, respectively (p < 0.0001). After adjustment, high sUA continued to predict a significantly higher risk of kidney disease development (HR 1.43, 95% CI 1.20-1.70). Conclusion. Male veterans with gout and sUA levels > 7 mg/di had an increased incidence of kidney disease.
引用
收藏
页码:1166 / 1172
页数:7
相关论文
共 50 条
  • [31] IRON METABOLISM: ASSOCIATION OF FERRITIN WITH SERUM URATE AND GOUT
    Fatima, T.
    Merriman, T.
    Iverson, C.
    Miner, J. N.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1187 - 1187
  • [32] FLUCTUATIONS IN SERUM URATE ARE RELATED TO GOUT FLARES IN THE NOR-GOUT STUDY
    Uhlig, T.
    Karoliussen, L.
    Sexton, J.
    Kvien, T. K.
    Haavardsholm, E. A.
    Perez-Ruiz, F.
    Hammer, H. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 384 - 385
  • [33] SERUM URATE AND GOUT IN 4663 YOUNG MALE WORKERS
    ZALOKAR, J
    LELLOUCH, J
    CLAUDE, JR
    SEMAINE DES HOPITAUX, 1981, 57 (13-1): : 664 - 670
  • [34] Critical appraisal of serum urate targets in the management of gout
    Lisa K. Stamp
    Nicola Dalbeth
    Nature Reviews Rheumatology, 2022, 18 : 603 - 609
  • [35] An artificial intelligence-based gout management system reduced chronic kidney disease incident and improved target serum urate achievement
    Qi, Han
    Lu, Jie
    Dalbeth, Nicola
    Sun, Mingshu
    Liu, Zhen
    Ji, Xiaopeng
    Ji, Aichang
    Wang, Can
    Sun, Wenyan
    Li, Xinde
    He, Yuwei
    Cui, Lingling
    Han, Lin
    Chen, Ying
    Yan, Fei
    Zhang, Yi
    Terkeltaub, Robert
    Li, Changgui
    RHEUMATOLOGY, 2024,
  • [36] Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
    Hosoya, Tatsuo
    Ohno, Iwao
    Nomura, Shinsuke
    Hisatome, Ichiro
    Uchida, Shunya
    Fujimori, Shin
    Yamamoto, Tetsuya
    Hara, Shigeko
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (06) : 876 - 884
  • [37] Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
    Tatsuo Hosoya
    Iwao Ohno
    Shinsuke Nomura
    Ichiro Hisatome
    Shunya Uchida
    Shin Fujimori
    Tetsuya Yamamoto
    Shigeko Hara
    Clinical and Experimental Nephrology, 2014, 18 : 876 - 884
  • [38] The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
    Pang, Lei
    Xue, Xiaomei
    He, Yuwei
    Wang, Can
    Han, Lin
    Li, Maichao
    Qi, Han
    Li, Changgui
    Lu, Jie
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 3937 - 3947
  • [39] Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States
    Raebel, Marsha
    Reifler, Liza
    Tabano, David
    Goddard, Kristin
    Sterrett, Andrew
    Cheetham, T. Craig
    Harrold, Leslie
    Sapp, Daniel
    Schmidt, Mark
    Nuevo, Javier
    Morlock, Robert
    Nichols, Gregory
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [40] SERUM URATE, GOUT, AND CARDIOVASCULAR DISEASE IN A RANDOMISED CONTROLLED TRIAL OF CANAKINUMAB: A CANTOS SECONDARY ANALYSIS
    Solomon, D.
    Glynn, R. J.
    MacFadyen, J. G.
    Libby, P.
    Thuren, T.
    Everett, B. M.
    Ridker, P. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 56 - 57